SAN FRANCISCO, March 4, 2025 /PRNewswire/ -- Sojern, the leading marketing platform built for hospitality, is excited to announce the addition of a fully managed email marketing service as part of its multichannel Commission offering. This industry-first solution streamlines marketing, making it easier to drive direct bookings, build guest loyalty, and reduce online travel agency (OTA) dependence—all within Sojern's transparent pay-for-performance commission model. Now available in the US and Canada, with additional countries coming soon.
Email campaigns are a powerful tool for hoteliers to engage travelers and build loyalty at every stage—from awareness to post-stay. With email marketing revenue expected to hit $17.9 billion by 2027, the channel continues to grow. However, time, expertise, and budget constraints often limit hoteliers' ability to run effective email campaigns.
Now, hoteliers can partner with Sojern to effortlessly execute high-performing email campaigns without the need for in-house resources. Powered by Sojern's AI-driven marketing platform, this new fully managed service combines Sojern's Guest Marketing Suite with the expertise of email designers and copywriters to ensure seamless campaign creation, deployment, performance and measurement. Sojern's email solution seamlessly connects with the hotel's property management system (PMS) to unlock powerful guest insights, enabling targeted email campaigns that drive engagement and direct bookings. Automated reconciliation further streamlines operations, allowing hoteliers to focus on the guest experience rather than manual tasks.
"Today's travelers increasingly seek personalized experiences, from their destination choices to their on-property stays," said Noreen Henry, Chief Revenue Officer at Sojern. "In fact, 90% of consumers expect brands to understand and anticipate their needs. As guests invest more in memorable and tailored experiences, they expect the same level of personalization from hotels before they've even arrived. With Sojern's fully-managed email solution, hotel marketers can deliver timely, branded content that drives engagement, direct bookings, and loyalty—overcoming traditional bandwidth and budget hurdles without additional work."
Cultivate Guest Relationships to Drive Direct Bookings
While many hotels still rely on bookings from OTAs, and will continue to in some capacity, the industry is shifting. Skift projects that by 2030, direct digital channels are expected to surpass OTAs as the dominant distribution channel for hoteliers, with an estimated $409 billion in direct bookings compared to $333 billion from OTAs. Sojern's fully managed email service helps hoteliers capitalize on this shift by delivering brand-aligned email campaigns that engage past guests, encourage repeat stays, reduce OTA dependence, and recapture abandoned bookings. And since repeat customers spend 67% more than new guests, investing in customized branded email campaigns isn't just smart—it's a revenue-driving necessity.
Early adopter Nicole Willams, Principal/VP Sales & Marketing, Daryon Hotels International said, "Working with Sojern has been a fantastic experience. Their email marketing campaigns have been a game-changer, helping us reach the right audience and drive more bookings. The process is seamless, the reporting is clear, and the results speak for themselves."
Pay Only for Results
Budget constraints often limit hotel marketers' abilities to get their brand in front of potential travelers. Rather than front-loading costs, Sojern's pay-for-performance pricing model is tied directly to revenue, allowing hoteliers to participate in managed email campaigns by only paying for performance.
Beyond reducing upfront costs, Sojern's multichannel approach allows hoteliers to ensure every touchpoint works together seamlessly to maximize conversions. With sophisticated attribution, hoteliers are able to engage travelers across channels, optimizing marketing spend and effectiveness to maximize ROI.
To learn more about Sojern's fully-managed email offering as part of its Commission solution, hoteliers can join the waitlist here.
About Sojern
Sojern is the leading marketing platform built for hospitality, designed to boost growth and profitability for the travel industry. The Sojern marketing platform is a set of easy-to-use software and services that delivers unrivaled traveler insight, intelligent audiences, multichannel activation and optimization, and a connected guest experience—all in one place. More than 10,000 travel marketers rely on our platform annually to find, attract, convert and engage travelers. Founded in 2007, Sojern is headquartered in San Francisco, California with teams in the Americas, Europe, Middle East and Africa, and Asia Pacific.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Sojern Introduces Fully Managed Email Campaigns--Hoteliers Pay for Performance
|
OXFORD, United Kingdom and HOUSTON, June 5, 2026 /PRNewswire/ -- Optellum, a leader in AI-enabled lung cancer diagnostics, today announced that it has surpassed 250 clinical sites and analyzed more than 3 million cases to date. This milestone underscores Optellum's commitment to empowering health systems and clinical care teams with the tools needed to identify, prioritize, and manage high-risk lung nodules more effectively. This commercial momentum is supported by first-of-their-kind partnerships across major markets, including with Bristol Myers Squibb in the US, and with the NHS and Intuitive Surgical to support end-to-end AI & robot lung cancer pathways in the UK. It is also reflected in established and new customer deployments at leading health systems, including the University of Pennsylvania Health System, Vanderbilt University Medical Center, and Oxford University Hospitals.
The scale of Optellum's impact is accelerating rapidly, and the company is now helping one patient every 14 seconds. Optellum pioneered the world's first FDA-cleared, CE-marked, and Medicare-reimbursed AI solution for image-based lung cancer risk stratification – Lung Cancer Prediction (LCP) AI, under the CPT codes 0721T and 0722T. LCP AI is helping to reduce the uncertainty associated with indeterminate lung nodules, ensuring that no nodule patient is left behind. Further, the wraparound Virtual Nodule Clinic (VNC) solution supports guideline-aligned decisions and has been shown to improve clinicians' efficiency while reducing time to recommended treatment.[1]
This growth reflects a broader shift toward the adoption of evidence-based innovation in thoracic care. Optellum continues to expand LungOSⓇ, its end-to-end AI-powered lung health platform, powered by the world's first Thorax CT Foundation Model built for real-world precision lung care. This foundation model is the only model in the world to leverage DART, the world's largest lung cancer CT dataset. LungOSⓇ brings VNC together with modules for triage and detection,[2] diagnostic support,[3] and therapy guidance.[4] Looking ahead, Optellum is poised to expand its clinical suite with the upcoming European launch of LungDetect, an exciting addition designed to simplify and accelerate nodule identification and characterization.
"Optellum is incredibly proud to be helping more health systems and clinicians provide timely, life-saving care to a growing number of patients," said Dr. Johnathan Watkins, Optellum's CEO. "Reaching 250 sites and analyzing millions of cases each year is a testament to the dedication of our team and the trust of our clinical partners. However, we are just getting started; we continue to build LungOSⓇ into the must-have "operating system" for lung cancer and thoracic care more broadly. We invite the global healthcare community to join us on our mission to help solve lung cancer by ensuring early diagnosis and early intervention become the standard for everyone everywhere."
Results from Optellum's continued growth and real-world clinical use will continue to be shared with clinicians, healthcare leaders, and policymakers to reach the broader goal of improving outcomes for every thoracic care team, in every hospital, for every patient.
About Optellum
Optellum is a commercial-stage AI healthcare company dedicated to revolutionizing early diagnosis and treatment of lung disease, starting with one of the deadliest, lung cancer.
Optellum is building LungOSⓇ, the end-to-end AI-powered platform for thoracic care. Its flagship product, Virtual Nodule Clinic (VNC) with Lung Cancer Prediction AI (LCP), is the world's first FDA-cleared and reimbursed software-as-a-medical-device (SaMD) solution for AI-powered lung cancer prioritization and diagnostic support. Clinicians trust the Optellum solution to aid them in making the most appropriate life-saving treatment decisions for their patients. Backed by real-world clinical evidence, Optellum's solution accelerates the diagnostic care pathway by enabling early patient identification, enhancing prioritization, and improving clinicians' efficiency, reducing time to guideline-recommended treatment. Optellum VNC is FDA cleared, CE-MDR marked, UKCA marked, and TGA-approved.
Optellum is headquartered in Oxford, UK, and has an office in Houston, Texas, US.
[1] Hill NR et al. Employment of artificial intelligence for early lung cancer diagnosis: a retrospective cohort study. BMJ Open Respiratory Research. 2025;12: e003225. https://doi.org/10.1136/bmjresp-2025-003225
[2] Both text-based detection with Patient Discovery and Patient Safety Net as well as image-based detection. Product availability depends on your region, please contact Optellum for more information.
[3] Commercially available in the US, EU/UK, and Australia.
[4] Pending; for research use only
Media Contact
marketing@optellum.com
OXFORD, United Kingdom and HOUSTON, June 5, 2026 /PRNewswire/ -- Optellum, a leader in AI-enabled lung cancer diagnostics, today announced that it has surpassed 250 clinical sites and analyzed more than 3 million cases to date. This milestone underscores Optellum's commitment to empowering health systems and clinical care teams with the tools needed to identify, prioritize, and manage high-risk lung nodules more effectively. This commercial momentum is supported by first-of-their-kind partnerships across major markets, including with Bristol Myers Squibb in the US, and with the NHS and Intuitive Surgical to support end-to-end AI & robot lung cancer pathways in the UK. It is also reflected in established and new customer deployments at leading health systems, including the University of Pennsylvania Health System, Vanderbilt University Medical Center, and Oxford University Hospitals.
The scale of Optellum's impact is accelerating rapidly, and the company is now helping one patient every 14 seconds. Optellum pioneered the world's first FDA-cleared, CE-marked, and Medicare-reimbursed AI solution for image-based lung cancer risk stratification – Lung Cancer Prediction (LCP) AI, under the CPT codes 0721T and 0722T. LCP AI is helping to reduce the uncertainty associated with indeterminate lung nodules, ensuring that no nodule patient is left behind. Further, the wraparound Virtual Nodule Clinic (VNC) solution supports guideline-aligned decisions and has been shown to improve clinicians' efficiency while reducing time to recommended treatment.[1]
This growth reflects a broader shift toward the adoption of evidence-based innovation in thoracic care. Optellum continues to expand LungOSⓇ, its end-to-end AI-powered lung health platform, powered by the world's first Thorax CT Foundation Model built for real-world precision lung care. This foundation model is the only model in the world to leverage DART, the world's largest lung cancer CT dataset. LungOSⓇ brings VNC together with modules for triage and detection,[2] diagnostic support,[3] and therapy guidance.[4] Looking ahead, Optellum is poised to expand its clinical suite with the upcoming European launch of LungDetect, an exciting addition designed to simplify and accelerate nodule identification and characterization.
"Optellum is incredibly proud to be helping more health systems and clinicians provide timely, life-saving care to a growing number of patients," said Dr. Johnathan Watkins, Optellum's CEO. "Reaching 250 sites and analyzing millions of cases each year is a testament to the dedication of our team and the trust of our clinical partners. However, we are just getting started; we continue to build LungOSⓇ into the must-have "operating system" for lung cancer and thoracic care more broadly. We invite the global healthcare community to join us on our mission to help solve lung cancer by ensuring early diagnosis and early intervention become the standard for everyone everywhere."
Results from Optellum's continued growth and real-world clinical use will continue to be shared with clinicians, healthcare leaders, and policymakers to reach the broader goal of improving outcomes for every thoracic care team, in every hospital, for every patient.
About Optellum
Optellum is a commercial-stage AI healthcare company dedicated to revolutionizing early diagnosis and treatment of lung disease, starting with one of the deadliest, lung cancer.
Optellum is building LungOSⓇ, the end-to-end AI-powered platform for thoracic care. Its flagship product, Virtual Nodule Clinic (VNC) with Lung Cancer Prediction AI (LCP), is the world's first FDA-cleared and reimbursed software-as-a-medical-device (SaMD) solution for AI-powered lung cancer prioritization and diagnostic support. Clinicians trust the Optellum solution to aid them in making the most appropriate life-saving treatment decisions for their patients. Backed by real-world clinical evidence, Optellum's solution accelerates the diagnostic care pathway by enabling early patient identification, enhancing prioritization, and improving clinicians' efficiency, reducing time to guideline-recommended treatment. Optellum VNC is FDA cleared, CE-MDR marked, UKCA marked, and TGA-approved.
Optellum is headquartered in Oxford, UK, and has an office in Houston, Texas, US.
[1] Hill NR et al. Employment of artificial intelligence for early lung cancer diagnosis: a retrospective cohort study. BMJ Open Respiratory Research. 2025;12: e003225. https://doi.org/10.1136/bmjresp-2025-003225
[2] Both text-based detection with Patient Discovery and Patient Safety Net as well as image-based detection. Product availability depends on your region, please contact Optellum for more information.
[3] Commercially available in the US, EU/UK, and Australia.
[4] Pending; for research use only
Media Contact
marketing@optellum.com
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Optellum Celebrates Accelerating Impact in Lung Cancer Care; Now at Over 250 Sites and Growing
